Biogen's progressive vision loss drug fails in late-stage clinical trials

A gene therapy for progressive vision loss developed by Biogen Inc. has failed in late-stage clinical trials, the Cambridge biotech said Friday.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.